Integrated Diagnostics Holdings (IDHC) Fair Value & Analysis
Healthcare · GB · Market cap $34.9B
Fair value as of: Jun 26, 2026
From 26 valuation models · updated 18 days ago
Fair value updated Jun 26, 2026 — revised from $0.0100 to $0.0053 (−47.3%) since Jun 24, 2026. Share price −2.3% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0030 – $0.0075 · the $0.0050 price screens below the $0.0053 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Integrated Diagnostics Holdings (IDHC) currently trades at $0.0050, while our model-based Fair Value estimate is $0.0053 — implying the stock looks roughly 5.0% fairly valued today. We read business quality at 71/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Integrated Diagnostics Holdings generated revenue of $6.8B at a net margin of 17.4%. Revenue grew 31.0% year over year. It earns a return on equity of 34.1%. The balance sheet holds a net cash position of $57.6M. Fundamentals as of Jun 26, 2026
For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside — at 5%, IDHC screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron emission tomography - computed tomography (PET-CT), MRI, computed tomography (CT), mammography, ultrasound, X-Ray, electromyography, electroencephalography, electroencephalogram, and electrocardiogram, as well as operates cath lab facilities. It operates in Egypt, Sudan, Nigeria, and the Kingdom of Saudi Arabia. The company was founded in 1979 and is based in Saint Helier, Jersey.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Integrated Diagnostics Holdings reported revenue of $7.9B in FY2025 versus $5.2B in FY2021, a compound +10.7%/yr. Reported net income was $1.3B in FY2025, compounding −2.8%/yr from FY2021.
Is IDHC fairly valued? → Check now
Recent news
- Top UK Growth Companies With Insider Ownership May 2026
- UK Growth Companies With High Insider Ownership
- Top UK Growth Companies With High Insider Ownership In May 2026
- UK Growth Stocks Insiders Are Eager To Own
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | 8,423 MXN | 3,691 MXN | -56% |
| Danaher Corporation DHR | $183.63 | $87.65 | -52% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $541.31 | $255.77 | -53% |
| Lonza Group LZAGY | $63.74 | $25.98 | -59% |
| Agilent Technologies, Inc A | $126.67 | $63.09 | -50% |
| Waters Corporation WAT | $363.18 | $113.71 | -69% |
| IQVIA Holdings IQV | $182.17 | $119.25 | -35% |
| Natera, Inc NTRA | $216.50 | $39.79 | -82% |
| Mettler-Toledo International Inc MTD | $1,154 | $547.22 | -53% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Integrated Diagnostics Holdings (IDHC) undervalued?
What is the fair value of IDHC?
What is the quality score of IDHC?
What is the revenue of Integrated Diagnostics Holdings (IDHC)?
What is the net profit margin of IDHC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Integrated Diagnostics Holdings analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.